Fortune Magazine - How A.I. Is Finding New Cures in Old Drugs
CMT News - Short-term PXT3003 Treatment Delays Disease Onset in Rat Model of CMT1A, Study Shows
The Sun - Rare ‘invisible’ and inherited disease leaves adults with strength of a child...
WCBS - Alzheimers, then Tchaikovsky...
WCBS - Reversing Peripheral Nerve Damage
WCBS - What’s Pleotherapy?
WCBS - Le President de la Republique Wants To Know...
WCBS - The Piano’s Loss Was Science’s Gain
The Straits Times - China seeks new markets for ancient medicines as it modernises TCM remedies
CMT News - International CMT&Me Observational Study to Explore the Impact of CMT Using an App
BioWorld - Pharnext shares rise on phase III readout in CMT1A disease
JUNKIES.tech - Pharnext’s Drug Combo for Uncommon Genetic Nerve Dysfunction Nails Part III
CMT News - PXT3003 Eases Disability, Found Safe in CMT1A Patients, Phase 3 Trial Shows
FierceBiotech - Pharnext muscle wasting phase 3 hits primary endpoint
LaBiotech.eu - Drug Combination for Rare Genetic Nerve Disorder Nails Phase III
BioWorld - Pharnext shares rise on phase III readout in Charcot-Marie-Tooth disease
RARE Daily - Pharnext Reports Positive Topline Results from Late-Stage Charcot-Marie-Tooth Trial
EndPoint News - Pharnext rare disease drug scores in late-stage study, teeing up applications at the FDA and EMA
BioCentury - Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data
BioTuesday - Pharnext platform taps genomic data, AI for new combination medicines
DDNews - Q&A: Pharnext and Pleotherapy
RARECast - Pharnext Takes a Unique Twist on Repurposing Drugs for Rare Diseases
Forbes - Paris Beckons To U.S. Biotech Investors
ABC30 Action News - Charcot-Marie-Tooth Treatment: CMT
Pharmaceutical Processing - Two drugs can be better than one
ThePharmaleter - Pharnext surge levels off as investors take in 20 million euro Chinese medicine deal
CFI.cn - Tasly Pharmaceutical Group：Allying with Pharnext to strengthen presence in innovativ
BioWorld - Pharnext inks three-part pact with China's Tasly
BioCentury - Pharnext, Tasly to form drug combo JV
GEN News - Tasly, Pharnext partner on drug combinations, including lead phase III CMT1A therapy
Page 1 of 2